@AndrewCurran_
Their CEO, Alex Zhavoronkov, told CNBC that Insilico has already developed at least 28 drugs using generative AI tools, with nearly half already at a clinical stage. They develop their models in Canada and the ME, and then conduct the early preclinical drug development in China. https://t.co/Z01uwEpJuK